NNNeeran Narainswami

Neeran Narainswami

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Neeran Narainswami has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative effectiveness and safety of adjunctive methotrexate in rhegmatogenous retinal detachment complicated by or at high risk for proliferative vitreoretinopathy: a systematic review and meta-analysis

    by Renata Ramos Stropp, Tiago Nelson de Oliveira Rassi, Lúcio Roberto Cançado Castellano, João Guilherme Gomes Pedrosa, Neeran Narainswami, Gabrielle de Lacerda Dantas Henrique, Lucas Valadão de Brito Soares, Carlos Augusto Moreira-Neto, Michel Eid Farah, Maurício Maia

    Purpose: To evaluate the efficacy and safety of adjunctive methotrexate (MTX) in vitreoretinal surgery for rhegmatogenous retinal detachment (RRD) complicated by or at high risk for proliferative vitreoretinopathy (PVR). Methods: This PRISMA-compliant systematic review and meta-analysis (PROSPERO CRD420261281220) searched PubMed, Embase, CENTRAL, and Web of Science through October 16, 2025. Randomized trials, comparative observational studies, and case series were included. Comparative and single-arm data were analyzed separately using random-effects models. Primary outcomes were final retinal reattachment and best-corrected visual acuity (BCVA); postoperative PVR and adverse events were secondary outcomes. Results: Sixteen reports met the eligibility criteria, with 14 unique studies contributing to quantitative synthesis. MTX was associated with a lower risk of postoperative PVR (6 studies; 131 MTX vs. 138 controls; RR 0.56, 95% CI 0.40–0.77; p = 0.004; I²=0%) and better BCVA in the primary analysis (MD − 0.20 logMAR, 95% CI − 0.34 to − 0.06; I²=12.3%), but not with improved final retinal reattachment (8 studies; 215 MTX vs. 207 controls; RR 1.07, 95% CI 0.90–1.28; p = 0.412; I²=56.7%). However, the association with better BCVA was attenuated and no longer statistically significant after studies at critical risk of bias were excluded. Single-arm analyses yielded a pooled reattachment rate of 80% (95% CI 75–85%) and postoperative PVR rate of 22% (95% CI 15–31%). Adverse events were predominantly mild, reversible corneal complications, reported mainly with repeated MTX injections. Certainty of evidence was very low across major efficacy outcomes. Conclusions: Adjunctive MTX was associated with reduced postoperative PVR but not with improved final retinal reattachment. Although the primary analysis suggested modestly better postoperative BCVA, this finding was not robust to the exclusion of studies at critical risk of bias. Given the very low certainty of evidence, these findings are hypothesis-generating rather than practice-changing. Larger randomized trials with standardized MTX regimens and outcome definitions are needed.

  • Macular edema and intraocular pressure outcomes after periocular vs topical corticosteroids after phacoemulsification: systematic review and meta-analysis

    by Pedro Henrique Ferrazza Sperotto, Nuno Rodrigues Alves, Carolina Carvalho Soares Valentim, Neeran Narainswami, Guilherme Melchior Maia Lopes, Eduardo de Carvalho Mazzocato, Marco Antonio Ferrazza Sperotto, Melis Kabaalioglu Guner

    Topic: Postoperative inflammation after phacoemulsification is routinely managed with topical corticosteroids, while periocular administration may provide a sustained anti-inflammatory effect. Clinical Relevance: Pseudophakic cystoid macular edema (PCME) remains a leading cause of suboptimal visual recovery after cataract surgery. Periocular corticosteroid injections may offer a single-dose alternative to topical regimens, minimizing adherence-related limitations. Methods: Following PRISMA 2020 guidelines (PROSPERO CRD420250632011), PubMed, Embase, and the Cochrane Central Registered of Controlled Trials (CENTRAL) were searched from inception to December 1, 2025, for studies comparing intraoperative periocular injections vs postoperative topical corticosteroids in adults undergoing uneventful phacoemulsification. Primary outcomes were PCME incidence and postoperative intraocular pressure (IOP). Corrected distance visual acuity (CDVA) was a secondary outcome. Data were pooled using a random-effects model. Results: 10 studies involving 57 564 eyes were analyzed. PCME incidence was comparable between groups (5 studies, 56 766 eyes; 1.10% periocular vs 1.40% topical; risk ratio, 0.84; 95% CI, 0.55-1.28; P = .42; I 2 = 65%). 8 studies (1829 eyes) showed no clear difference in postoperative IOP (mean difference [MD], 0.28 mm Hg; 95% CI, −0.20 to 0.77; P = .25; I 2 = 65%). CDVA outcome was similar between groups (4 studies, 1188 eyes; MD, −0.01 logMAR; 95% CI, −0.03 to 0.01; P = .31; I 2 = 0%). Follow-up varied by outcome, extending from approximately 1 month to 120 days. Conclusions: Current evidence found no clear differences in PCME risk, postoperative IOP, or CDVA between periocular and topical corticosteroids after uneventful phacoemulsification. Findings should be interpreted cautiously given the heterogeneity and low certainty evidence. Clinical use should consider drug, formulation, dose, injection route, and the need for longer-term monitoring.

  • Open Access

    Functional Outcomes and Ocular Safety of Subretinal AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: A Systematic Review and Meta-Analysis

    by Carlos Roberto Montes-De-Oca-Saucedo, José Antonio Garza-Cruz, Bruno Briceño-Villardaga, Ingrid Vanessa Infante-Lee, Rafael Chavarría-Rojas, Natalie Carled Bermejo-Valero, Adolfo Soto-Domínguez, Neeran Narainswami

    Background/Objectives: We aimed to provide an updated synthesis of the efficacy and ocular safety of subretinal adeno-associated viral (AAV) RPGR gene therapy for retinitis pigmentosa GTPase regulator (RPGR)-associated X-linked retinitis pigmentosa (RPGR-XLRP) and to assess the certainty of the available evidence. Methods: We performed a PROSPERO-registered (CRD420251163589), PRISMA 2020 systematic review and meta-analysis using database and trial-registry searches. The primary microperimetry synthesis was restricted to mesopic Macular Integrity Assessment (MAIA) 68-loci acquisitions; continuous-outcome syntheses were conducted at the cohort level, using observed paired-eye contrasts when available; dose levels were interpreted within clinical programs; and above-maximum-tolerated-dose and peripheral-injection cohorts were reported separately. Random-effects analyses used DerSimonian–Laird models with Hartung–Knapp–Sidik–Jonkman small-sample correction. Risk of bias and certainty were assessed with design-matched tools and Grading of Recommendations Assessment, Development and Evaluation (GRADE). Results: The quantitative synthesis included four trials reported in five publications (128 participants; AAV8, AAV5, and AAV2tYF platforms). Mesopic retinal sensitivity numerically favored treatment, but the pooled differences were not statistically significant at six months (mean difference [MD] +1.11 dB; 95% confidence interval [CI], −0.88 to +3.09) or twelve months (MD +0.97 dB; 95% CI, −3.99 to +5.94). Best-corrected visual acuity showed no statistically significant pooled difference (MD +0.94 letters; 95% CI, −4.97 to +6.85). The six-month ≥10-letter low-luminance responder estimate favored treatment, but was nonsignificant and attenuated by twelve months; no primary pooled efficacy outcome reached significance under small-sample-adjusted inference. Certainty was very low for functional outcomes and low for safety outcomes. Uncontrolled treated-eye proportions were 80.8% for intraocular inflammation, 17.0% for ocular serious adverse events, and 4.3% for central-injection retinal detachment. Conclusions: Current evidence does not establish a clinically actionable functional benefit, although a modest true effect cannot be excluded. Clinically relevant ocular safety signals were observed, but the estimates were uncontrolled and program dependent. Adequately powered randomized trials with standardized functional endpoints, optimized subretinal delivery strategies, and careful within-program dose selection are needed.

  • Open Access

    Impact of glaucoma on outcomes after epiretinal membrane surgery. a pairwise and post-hoc single-arm meta-analysis

    by Raphaela Masetto C. Fuganti, Tiago Nelson O. Rassi, Maikon V. Fuganti, Neeran Narainswami, Jorge Rocha, Sunir Garg, Mauricio Maia, Antonio Marcelo B. Casella, Antonio Marcelo B. Casela

    Purpose To evaluate whether glaucoma modifies functional, anatomical, and intraocular pressure outcomes after pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling for idiopathic epiretinal membrane (ERM). Methods PubMed, Embase, and Cochrane Library were searched through April 27, 2025, for comparative studies of PPV with ILM peeling in glaucomatous versus non-glaucomatous eyes. Primary outcome was the change (Δ) in best-corrected visual acuity (BCVA); secondary outcomes were changes (Δ) in central macular thickness (CMT), intraocular pressure (IOP), and number of glaucoma medications. Risk of bias was assessed with ROBINS-I and certainty of evidence with GRADE. A post-hoc single-arm synthesis summarized outcomes in glaucomatous eyes. PROSPERO registration: CRD420251041680. Results Six studies (779 eyes: 256 glaucomatous, 523 non-glaucomatous) contributed to the pairwise meta-analysis, and three additional studies (325 glaucomatous eyes) informed single-arm data. Non-glaucomatous eyes achieved greater BCVA improvement (mean difference − 6.95 ETDRS letters; 95% CI − 11.54 to − 2.35; p < 0.01) and larger CMT reduction after outlier removal (+ 39.50 μm; 95% CI 11.48 to 67.53; p = 0.006). Glaucomatous eyes still improved significantly (BCVA + 10.03 ETDRS letters; CMT − 102.05 μm), with stable IOP (Δ + 0.64 mmHg; p = 0.12) but increased medication use (+ 0.61 drops; p < 0.001). Follow-up ranged from 6 to 12 months, and overall evidence certainty was high. Conclusions Glaucoma attenuates, but does not eliminate, the visual and anatomical benefits of ERM surgery. However, central visual field safety cannot be guaranteed, particularly in moderate to advanced disease. Careful postoperative glaucoma monitoring and individualized management are recommended.

  • Slow-Coagulation Cyclophotocoagulation Versus Conventional Continuous Wave Cyclophotocoagulation and Micropulse Cyclophotocoagulation for the Treatment of Glaucoma: A Systematic Review and Meta-Analysis

    by Neeran Narainswami, Matheus Pedrotti Chavez, Pedro Henrique Ferrazza Sperotto, Nuno Rodrigues Alves, Guilherme Melchior Maia Lopes, Eduardo de Carvalho Mazzocato, Carolina Carvalho Soares Valentim, Nagib du Toit, Mohamed Md Khodeiry

    Précis: SC-TSCPC significantly lowers intraocular pressure more effectively than MP-TSCPC and performs similarly to CW-TSCPC. Safety and visual outcomes are comparable, supporting its use as a nonincisional treatment option for various glaucoma patients. Introduction: Slow-coagulation transscleral cyclophotocoagulation (SC-TSCPC) is an emerging laser modality for glaucoma management designed to lower intraocular pressure (IOP) with possible fewer complications than conventional continuous-wave (CW-TSCPC) and micropulse (MP-TSCPC) approaches. We conducted a systematic review and meta-analysis to compare the efficacy and safety of SC-TSCPC with those of MP-TSCPC and CW-TSCPC. Methods: PubMed, Embase, and Cochrane Library were searched from inception through December 2025 for studies comparing SC-TSCPC with MP-TSCPC or “conventional” CW-TSCPC. Primary outcomes were IOP reduction from baseline and IOP at last follow-up. Secondary outcomes included medication burden, best-corrected visual acuity (BCVA), treatment success, and complications. We computed mean differences (MDs) for continuous endpoints and risk ratios (RRs) for binary endpoints, with 95% CIs. Results: Thirteen studies comprising 992 patients were included. SC-TSCPC achieved greater IOP reduction from baseline compared with MP-TSCPC ( MD 1.29 mm Hg, 95% CI 0.26–2.32, P =0.01, I 2 =0%) but was comparable to conventional CW-TSCPC ( MD -1.00 mm Hg, 95% CI −3.14 to 1.13, P =0.36). IOP at last follow-up, number of medications, BCVA, treatment success, and total complication rates for SC-TSCPC were similar to those for MP-TSCPC or CW-TSCPC. Conclusion: SC-TSCPC may provide comparable IOP control to CW-TSCPC and appears more effective than MP-TSCPC in lowering IOP, with a similar safety profile. It may represent a viable nonincisional treatment option for glaucoma, including patients who retain visual potential. These results require cautious interpretation due to the overall low-to-very low quality of evidence and significant heterogeneity among studies. Larger randomized studies are needed to validate these findings.